Literature DB >> 6593220

In vitro activity of ciprofloxacin against clinical isolates of Chlamydia trachomatis.

H Meier-Ewert, G Weil, G Millott.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6593220     DOI: 10.1007/bf01977501

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


× No keyword cloud information.
  5 in total

1.  A method for testing the antibiotic susceptibility of Chlamydia trachomatis in a cell culture system.

Authors:  G L Ridgway; J M Owen; J D Oriel
Journal:  J Antimicrob Chemother       Date:  1976-03       Impact factor: 5.790

2.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

3.  In vitro activity of norfloxacin against Chlamydia trachomatis.

Authors:  H Meier-Ewert; G Weil; G Millott
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

4.  The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and Mycoplasmas in vitro.

Authors:  G L Ridgway; G Mumtaz; F G Gabriel; J D Oriel
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

5.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

  5 in total
  4 in total

1.  In vitro activity of the two new 4-quinolones A56619 and A56620 against Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum and Gardnerella vaginalis.

Authors:  K H Tjiam; J H Wagenvoort; B van Klingeren; P Piot; E Stolz; M F Michel
Journal:  Eur J Clin Microbiol       Date:  1986-10       Impact factor: 3.267

Review 2.  Antimicrobial chemotherapy of chlamydial infection: where next?

Authors:  G L Ridgway
Journal:  Eur J Clin Microbiol       Date:  1986-10       Impact factor: 3.267

3.  Interactions of ciprofloxacin with clindamycin, metronidazole, cefoxitin, cefotaxime, and mezlocillin against gram-positive and gram-negative anaerobic bacteria.

Authors:  J L Whiting; N Cheng; A W Chow
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

4.  Is pelvic inflammatory disease an indication for treatment with ciprofloxacin?

Authors:  D Hägele; V Chyský
Journal:  Infection       Date:  1988       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.